重视潜质未定的克隆性造血和意义未定的克隆性血细胞减少症的诊断和治疗  

The state of the art:diagnosis and therapeutic interventions of clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance

作　　者：肖志坚 Xiao Zhijian(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China;Tianjin Institutes of Health Science,Tianjin 301600,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津300020 [2]天津医学健康研究院,天津301600

出　　处：《中华血液学杂志》2025年第1期5-8,共4页Chinese Journal of Hematology

基　　金：国家自然科学基金(82170139);中国医学科学院医学与健康科技创新工程项目(2023-I2M-2-007、2022-I2M-1-022)。

摘　　要：2022年提出的造血淋巴肿瘤WHO分型(WHO 2022)以及髓系肿瘤和急性白血病国际共识分型(ICC)已将潜质未定的克隆性造血(CHIP)和意义未定的克隆性血细胞减少症(CCUS)正式列入了髓系肿瘤分型。最近又相继提出了三个CHIP和CCUS髓系肿瘤转化分险的预测模型,并已开展了CHIP和CCUS干预治疗临床试验。为了规范CHIP和CCUS的诊断和治疗,本文就目前我国面临的挑战以及可能的解决方案做了探讨。Clonal hematopoiesis of indeterminate potential(CHIP)and clonal cytopenias of undetermined significance(CCUS)are included in both fifth edition of the World Health Organization classification(WHO 2022)and International Consensus Classification(ICC).Recently three models were developed for prediction of myeloid neoplasms risk and clinical trials are initiated to investigate potential treatments for CHIP and CCUS.Challenges in diagnosis and therapeutic intervention of CHIP and CCUS were discussed.

关 键 词：克隆性造血 潜质未定的克隆性造血 意义未定的克隆性血细胞减少症 诊断 治疗 

分 类 号：R73[医药卫生—肿瘤]